Evidence map›Paper›PMID 36494092›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Peptide Supramolecular Assembly-Instructed In Situ Self-Aggregation for Stratified Targeting Sonodynamic Therapy Enhancement of AIE Luminogens.

Weixi Jiang, Chen Cheng, Xiaoling Qiu, Li Chen, Xun Guo, Yuanli Luo, Jingxue Wang, Junrui Wang, Zhuoyan Xie, Pan Li and 4 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Weixi JiangDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.ORCID 0000-0002-7017-4570
Chen ChengDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Xiaoling QiuDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Li ChenDepartment of Intensive Care Unit, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Xun GuoDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Yuanli LuoDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Jingxue WangDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Junrui WangDepartment of Radiology, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Zhuoyan XieDepartment of Ultrasound, Chongqing General Hospital, NO. 118 Xingguang Avenue, Liangjiang New Area, Chongqing, 401147, P. R. China.
Pan LiDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Zhigang WangDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Haitao RanDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.
Zhiyi ZhouDepartment of General practice, Chongqing General Hospital, NO. 118 Xingguang Avenue, Liangjiang New Area, Chongqing, 401147, P. R. China.
Jianli RenDepartment of Ultrasound and Chongqing Key Laboratory of Ultrasound Molecular Imaging, the Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, P. R. China.ORCID 0000-0003-1276-780X
Dalian Medical University · CNFirst People's Hospital of Chongqing · CN

Funding

High-level Medical Reserved Personnel Training Project of Chongqing W0026Innovation Project of Chongqing Postgraduate Research CYB20154Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University 2020GDRC011Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University KR2019G001National Natural Science Foundation of China 81873901National Natural Science Foundation of China 82171946Postdoctoral Science Foundation of China 2022TQ0396Research and Frontier Exploration Key Project of Chongqing Science and Technology Commission cstc2019jcyj-zdxmX0020
6 · The paper itself

Abstract

The emergence of aggregation-induced emission luminogens (AIEgens) has attracted substantial scientific attention. However, their antitumor efficacy in photodynamic therapy (PDT) is significantly restricted by the poor water solubility and limited treatment depth. Therefore, a novel AIEgens-involved therapeutic platform with good permeability and bioavailability is urgently required. Herein, supramolecular chemistry is combined with the AIEgen bis-pyrene (BP) to construct a peptide-AIEgen hybrid nanosystem (PAHN). After intravenous injection, the versatile nanoplatform not only improved the hydrophilicity of BP but also achieved stratified targeting from tumor to mitochondrial and induced mitochondrial dysfunction, thus activating caspase-3 upregulation. Then, sonodynamic therapy (SDT), an alternative modality with high tissue penetrability, is performed to evoke reactive oxygen species (ROS) generation for BP. More importantly, since the hydrophilic shell is separated from the nanosystem by the specific cleavage of caspase-3, the resulting decrease in hydrophilicity induced tight self-aggregation of PAHN residues in situ, further allowing more absorbed energy to be used for ROS generation under ultrasound irradiation and enhancing SDT efficacy. Moreover, severe oxidative stress resulting from ROS imbalance in the mitochondria initiates the immunogenic cell death process, thus evoking antitumor immunogenicity. This PAHN provides prospective ideas into AIE-involved antitumor therapy and design of peptide-AIEgens hybrids.

Indexed as

PhotochemotherapyCaspase 3PeptidesProspective StudiesReactive Oxygen SpeciesCaspase 3PeptidesReactive Oxygen Speciesaggregation-induced emissionin situ self-aggregationpeptide-based supramolecular self-assemblysonodynamic therapystratified targeting

Identifiers

PMID36494092
PMCPMC9896067
OpenAlexW4311027843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.